Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology-Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2014
  • Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Duke University School of Medicine 2008
  • Ph.D., Duke University 2007
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2014 - 2017
• Research
• 

  Selected Grants

  • BMS CA209-848 awarded by Bristol-Myers Squibb Company 2019 - 2024
  • MedImmune Panc D607C00005 awarded by AstraZeneca LP 2018 - 2023
  • A Phase 1/2 study of exploring the safety tolerablility and efficacy of Epacadostat in combination with Durvalumab in subjects with selected advanced solid tumors. awarded by Incyte Corporation 2016 - 2021
  • A platform study exploring the safety tolerability effects on the tumor microenvironment and efficacy of Pembroliumab (MK-3475) + INCB combination awarded by Incyte Corporation 2016 - 2021
  • A Phase I open label dose escalation safety and tolerability study of INCB054828 in subjects with advanced malignancies awarded by Incyte Corporation 2015 - 2020
  • AM0010-301 A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared awarded by ARMO BioSciences 2017 - 2020
  • BACCI - RU021416 Phase II Study awarded by Academic and Community Cancer Research United 2017 - 2020
  • A Phase 1/2 study of the safety, tolorability and efficacy of INCB24360 administered in combination with Nivolumab in select advanced cancers. awarded by Incyte Corporation 2015 - 2020
  • OncoMed OMP-313M32 awarded by OncoMed Pharmaceuticals 2017 - 2019
  • ATELIER ML39832 PI Initiated awarded by Genetech 2018
  • A Phase 2 proof of concept study of ACP-196 alone in combination with Pembrolizumab in subjects with advanced or metastatic pancreatic cancer. awarded by Acerta Pharma 2015 - 2018
  • A Multi center study of the Bruton's Tyrosine Kinase (BTK) inhibitor, Ibrutinib in combination with MEDI4736 awarded by Pharmacyclics, Inc. 2015 - 2018
  • Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer awarded by Department of Defense 2016 - 2017
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Mettu, NB, and Abbruzzese, JL. "Clinical Insights Into the Biology and Treatment of Pancreatic Cancer." Journal of Oncology Practice 12, no. 1 (January 2016): 17-23. (Review)  Full Text  Open Access Copy
    • Mettu, NB, Hurwitz, H, and Hsu, DS. "Use of molecular biomarkers to inform adjuvant therapy for colon cancer." Oncology (Williston Park, N.Y.) 27, no. 8 (August 2013): 746-754. (Review)
    • Mettu, NB, Hurwitz, H, and Hsu, DS. "Use of molecular biomarkers to inform adjuvant therapy for colon cancer." Oncology (United States) 27, no. 8 (January 1, 2013). (Review)
    • Stanifer, J, Mehta, R, Mettu, N, Sanders, J, and Setji, N. "Muehrcke's lines as a diagnostic clue to increased catabolism and a severe systemic disease state." The American Journal of the Medical Sciences 342, no. 4 (October 2011): 331-null.  Full Text
    • Mettu, NB, Stanley, TB, Dwyer, MA, Jansen, MS, Allen, JE, Hall, JM, and McDonnell, DP. "The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors." Mol Endocrinol 21, no. 10 (October 2007): 2361-2377.  Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.